Insider Trading June 30, 2026 04:45 PM

J.M. Smucker Executive Jill Penrose Executes $583,475 Share Sale Amid Analyst Optimism

CPO offloads 5,000 shares at $116.695 as Wall Street raises price targets on strong fiscal performance.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
SJM

Jill R. Penrose, the Chief People Officer at J.M. Smucker Co (NASDAQ:SJM), executed a direct sale of 5,000 common shares on June 29, 2026, totaling $583,475. The transaction occurred at a per-share price of $116.695, leaving Ms. Penrose with a direct holding of 15,795 shares and an additional 2,732 shares held indirectly through a 401(k) plan. This divestment takes place while the company's stock trades at $112.50, a level below the transaction price. The sale coincides with a period of heightened analyst confidence, as major financial institutions including UBS, Bernstein, TD Cowen, and Stifel have recently upgraded their outlooks on J.M. Smucker. These updates follow the company's fourth-quarter earnings report, which showed a 20% year-over-year increase in earnings per share to $2.77, surpassing analyst estimates. The company also released its initial fiscal 2027 guidance, which beat expectations on the bottom line. Despite the executive transaction, the broader market context for J.M. Smucker remains anchored by its long-standing dividend history and recent robust organic sales growth.

J.M. Smucker Executive Jill Penrose Executes $583,475 Share Sale Amid Analyst Optimism
SJM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Jill R. Penrose sold 5,000 shares at $116.695, reducing her direct stake to 15,795 shares while maintaining indirect holdings via a 401(k) plan.
  • Major financial institutions including UBS, Bernstein, TD Cowen, and Stifel have raised price targets following strong Q4 earnings and fiscal 2027 guidance.
  • The company reported a 20% year-over-year increase in EPS to $2.77 and achieved 6% organic sales growth driven by a 10% price increase.

Jill R. Penrose, serving as the Chief People Officer for J.M. Smucker Co (NASDAQ:SJM), has completed a significant transaction involving the company's equity. According to a filing submitted to the Securities and Exchange Commission on June 29, 2026, Ms. Penrose sold a total of 5,000 common shares. The transaction was executed at a price of $116.695 per share, resulting in a total value of $583,475. This direct sale reduces her immediate ownership stake in the consumer staples manufacturer.

Following the execution of this sale, Ms. Penrose's direct holdings in J.M. Smucker stand at 15,795 common shares. Her total equity exposure to the company is further expanded by an additional 2,732 shares held indirectly through a 401(k) plan. The timing of this divestment is notable given the current trading price of SJM stock, which stands at $112.50. This current market price sits below the $116.695 price point at which Ms. Penrose executed her sale.

Market analysis tools indicate that the stock may be trading slightly above its calculated Fair Value, yet the company has demonstrated significant shareholder value creation over the last twelve months, delivering a 23% return. J.M. Smucker continues to support its shareholder base through a consistent dividend policy, having maintained payments for 56 consecutive years. The current dividend yield stands at 3.8%, reflecting the company's commitment to income generation despite market fluctuations.

The executive transaction occurs against a backdrop of positive fundamental performance and analyst upgrades. J.M. Smucker recently reported fourth-quarter earnings per share of $2.77, representing a 20% increase compared to the previous year. This result surpassed the consensus estimates of several market analysts. Furthermore, the company released its initial fiscal 2027 outlook, which exceeded expectations regarding the bottom line.

In response to these financial results, several prominent financial institutions have adjusted their price targets for J.M. Smucker. UBS reiterated a Buy rating, citing stronger top-line growth and reduced operating expenses as key drivers for their optimism. Bernstein highlighted the company's impressive organic sales growth of 6%, noting that this growth was achieved despite a 4% decline in volumes, supported by a 10% increase in prices. TD Cowen has updated its earnings per share estimates for fiscal years 2027 and 2028 to $10.05 and $10.56, respectively. Stifel maintained a Hold rating but increased its price target, emphasizing the company's improved profit margins.

Risks

  • Current stock valuation appears slightly overvalued relative to calculated Fair Value according to market analysis, presenting potential downside risk.
  • Organic sales growth was achieved despite a 4% decline in volumes, indicating potential sensitivity to volume contraction in the consumer staples sector.
  • Executive divestment at a price above current trading levels may signal internal valuation perspectives, impacting investor sentiment in the broader market.

More from Insider Trading

Disc Medicine's Chief Legal Officer Executes $187,500 Stock Sale Under Pre-Arranged Plan Jun 30, 2026 Ionis Pharmaceuticals EVP Joseph Baroldi’s Spouse Executes Pre-Arranged Stock Sales and Acquisitions Jun 30, 2026 Ionis Pharmaceuticals Executive Offloads Shares Under Pre-Arranged Plan Jun 30, 2026 Ionis Pharmaceuticals Executive Disposes of Shares Under Pre-Arranged Plan Jun 30, 2026 Disc Medicine COO Jonathan Yu Executes $21,750 Stock Sale Under Pre-Arranged Trading Plan Jun 30, 2026